Alliance Global Partners lowered the firm’s price target on Acurx (ACXP) to $5 from $14 and keeps a Buy rating on the shares after the company reported Q4 results and provided clinical development updates for its lead compound ibezapolstat for the treatment of c. difficile infections. While the firm remains positive on the upcoming 2025 developments, it adjusted its price target given its new expectations for potential launch and the funding/partnership needs for ibezapolstat to come to market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP: